This inhibitory effect can also be seen at the level of leukemic progenitors and pore primitive, LTC-IC-derived progenitors (Fig 6), suggesting that clinical grade AHR agonists could be of future use in targeting CML stem cells [6]. Here, AHR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.